Podcasts

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Andrew Lipsky, MD, discusses data with pirtobrutinib in relapsed/refractory CLL and the effect of its FDA approval on sequencing decisions for this disease.

Adam Fox, MD, and Cynthia A. Schandl, MD, PhD, examined the expanding role of biomarker testing and genomic profiling in NSCLC across disease stages.

Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, discuss the ongoing development of subcutaneous isatuximab administration via an on-body injector for patients with multiple myeloma.

Dr Phillips discusses updated data from the EPCORE NHL-1 trial investigating epcoritamab monotherapy in patients with relapsed/refractory LBCL.

Breast cancer experts discuss adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways.

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

John O. Mascarenhas, MD, details the investigation of novel targeted therapies in patients with myeloproliferative neoplasms.

Drs Camidge and Call discuss Dr Call's career path, which transitioned from community oncology to full-time phase 1 research within community practice.

Dr Garcia-Manero contextualizes lisaftoclax's potential to improve outcomes historically achieved with azacitidine alone in higher-risk MDS.

Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with IMiDs.

Dr Falchi discusses why the FDA approval of epcoritamab plus lenalidomide/rituximab is clinically meaningful for relapsed/refractory follicular lymphoma.

Surbhi Sidana, MD, discusses the FDA approval of BVd for relapsed or refractory multiple myeloma.

Jonathan R. Strosberg, MD, reviews the clinical implications of PRRT with 177Lu-edotreotide for metastatic gastroenteropancreatic neuroendocrine tumors.

Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, co-hosted a discussion with Valentina Bonev, MD, DABS, FACS, FSSO, about the interplay between surgery and radiation in breast cancer care.

Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.

Dr Vulsteke discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer.

Drs Rotow and Woodard talk through recent updates to the perioperative non–small cell lung cancer treatment paradigm.

Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD, lead an OncLive Ask the Expert discussion on evolving imaging strategies in glioma.

Drs Camidge and Fleming discussed how Fleming's interest in biostatistics led to a multifaceted career in clinical trial design and analysis.

Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.

Dr Phull reviews findings from a translational study that longitudinally profiled the fecal microbiome of patients with newly diagnosed myeloma.

Drs Kim and Malhotra discuss factors that make IB6 unique vs other NSCLC biomarkers and the study of sigvotatug vedotin in previously treated NSCLC.

Drs Armstrong and Tawagi highlight chronic lymphocytic leukemia updates from the 2025 ASH Annual Meeting.

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

Camidge and Singer discuss how Singer's background in broadcasting and cable television has led to a career in promoting cancer awareness.

Drs Tiesi, Scholer, Golas, and Pletcher discuss the use of hepatic artery infusion in colon cancer and liver cancer management.